KINAXO
Key Facts
| Invested since | 2006 |
| Based in | Martinsried |
About the company
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare.
Exit since Feb. 2011. Purchaser: Evotec AG
Do you want to
know more about this company?
KINAXO in the news
More startups from Life Sciences
InCephalo develops exclusively local treatments for neurological diseases, with a focus on cancers in the brain (primary brain cancers as well as secondary brain cancers). The proprietary Compartment Lock technology, …
to InCephalo
Exit
Pioneer in the development of new therapeutics for heart disease
to CARDIOR
Exit
Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune …
to Rigontec
Exit
RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education …
to RIMASYS
C-mo Medical Solutions is an award-winning Digital Health start-up that develops solutions for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential …
to C-mo
WISE Srl is a Milan and Berlin-based company developing genuinely novel and minimally-invasive implantable leads for Neuromodulation and Neuromonitoring: highly conformable, stretchable, unbreakable and cheaper to produce.
to WISE
TECregen is pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses. The company’s innovative approach focuses on revitalizing and expanding thymic epithelial cells (TECs) to replenish T cells …
to TECregen
Since its operational start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular …
to HepaRegeniX
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
to faCellitate
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only …
to Akribion Therapeutics
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
to Refoxy Pharma
Symphera is a Munich-based startup that is revolutionizing laparoscopic surgery with an innovative system designed to eliminate the need for manual instrument changes. Founded in 2023, Symphera was incubated at …
to Symphera